GLOBAL COLON AND RECTAL CANCER DRUGS MARKET
Overview:
Colon and rectal cancer show several similar features. According to the U.S. The American Cancer Society (ACS) rate of colorectal cancer is growing among the millennial population. ACS also predicts, in 2018, colon cancer will reach up to 97,220 new patients along with 43,030 patients with rectal cancer in the American territory. Likewise, because of the growing chances of colorectal cancer, in May 2018, ACS developed its rules and regulations for colorectal cancer screenings and suggested beginning colorectal cancer screening at the age of 45 instead of age of 50.
Drivers:
Rising incidence and the majority of colon and rectal cancer globally and advancing investigation and development studies for colorectal cancer therapy had anticipated pushing the development of the colon and rectal cancer market soon. According to the data results of the American Cancer Society (ACS), in February 2018, colorectal cancer is the third standard cancer interpreted in men and women in the American regional market.
Based on the data findings of the Center for Disease Control and Prevention (CDC), in 2014, almost 139,992 American citizens were diagnosed with colorectal cancer, which includes 66,596 female patients and 73,396 male patients. In these data findings, almost 51,651 casualties occurred in the American market due to colorectal cancer. Among these casualties, 24,517 were women, and 27,134 were men patients. Likewise, based on the data report in 2012, gathered by the World Health Organization (WHO), colorectal cancer is the third standard cancer among male patients and the second standard cancer among female patients globally. Similarly, approximately 55% of cases occurred in developed territories.
๐๐จ ๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐๐ญ๐๐ฌ๐ญ ๐๐จ๐ฏ๐ข๐๐๐ ๐๐ฆ๐ฉ๐๐๐ญ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ @ https://www.coherentmarketinsights.com/insight/request-sample/2019
The development in research and development done by government and private healthcare institutions are promoting the growth of the global colon and rectal cancer drugs market. Till March 2018, the American Cancer Society (ACS) expend US$ 54 million in fundings on research on colon and rectal cancer concerning 92 research funds.
Market Restraints:
Development shortage in the neoadjuvant/adjuvant channel reps to treating the last stage of colorectal cancer displaying slight improvement in colon and rectal cancer drugs market. Based on the report established in 2016, by the National Center for Biotechnology Information (NCBI), the healthcare sector suffers from a shortage of clinical trials of perioperative, neoadjuvant, and adjuvant chemotherapy for colorectal liver metastases (CRLM) therapy.
Likewise, inappropriate restitution guidelines regarding colorectal cancer therapy in a few countries hinder the growth of the global colon and rectal cancer drugs market. Based on the comparison investigation issued in the American Society of Clinical Oncology (ASCO) 2018 conference, the estimation for metastatic colorectal cancer therapy in Washington is more elevated compared to British Columbia in Canada, resulting in the same outcome.
Regional Analysis:
Based on the regional market, the global colon and rectal cancer drugs market is divided into North America, Latin America, the Middle East, Asia Pacific, Africa, and Europe. North American market has a principal place in the colon and rectal cancer drugs market. After that, the European market comes in second place. It happens because of the rising incidence speed of colorectal cancer in these regional markets. Based on the report published in 2012, by the World Cancer Research Fund International, the most elevated pace of colorectal cancer has been recorded in the Republic of Korea, Slovakia, and Hungary respectively. Correspondingly, a short span ago, a considerable amount of colorectal cancer cases was recorded in Oceania and Europe territory, while it delivers the lower incidence rates in Africa and Asia regional market.
๐๐ฎ๐ฒ ๐๐จ๐ฐ ๐๐ง๐ ๐๐๐ญ ๐ ๐ฅ๐๐ญ ๐๐๐ ๐๐๐๐ ๐๐ ๐
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐จ ๐๐๐๐๐ฌ๐ฌ ๐ ๐ฎ๐ฅ๐ฅ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง @ https://www.coherentmarketinsights.com/promo/buynow/2019
Competitive Analysis:
Few of the major companies working in the global colon and rectal cancer drugs market contain Merck KGaA, Sanofi S.A. Sorrento Therapeutics, Takeda Pharmaceutical Company Ltd., AstraZeneca plc, Sirtex Medical Limited, Amgen Inc., Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo Company.
Major companies in the market are interested in the analysis and development of conducting clinical test studies and earning regulatory permission. In March 2018, Daiichi Sankyo began stage II research of DS-8201 in patients with HER2-expressing developed colorectal cancer. The beginning of HER2 stage clinical test analysis by Daiichi Sankyo for colorectal cancer treatment will allow improving the results in colorectal cancer patients. In March 2018, Bristol-Myers Squibbโs Opdivo (nivolumab) injection got authorized by the FDA. It is administrated intravenously for the therapy of adult and pediatric patients suffering from microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
Taxonomy:
The global colon and rectal cancer drugs market is segmented based on drug type, distribution channel, and the region as mentioned below:
By Drug Type:
โข Single Drug
o Colon Cancer
โข Avastin
โข Bevacizumab
โข Capecitabine
โข Cetuximab
โข Nivolumab
โข Oxaliplatin
โข Panitumumab
โข Others
o Rectal Cancer
โข Avastin
โข Capecitabine
โข Cyramza
โข Erbitux
โข Irinotecan Hydrochloride
โข Nivolumab
โข Others
o Combination Drug
โข Colon Cancer
โข CAPOX
โข FOLFIRI
โข FOLFIRI-CETUXIMAB
โข FOLFOX
โข XELIRI
โข Others
o Rectal Cancer
โข CAPOX
โข FOLFIRI-BEVACIZUMAB
โข FU-LV
โข XELIRI
โข XELOX
โข Others
By Distribution Channels:
โข Hospitals Pharmacies
โข Online Pharmacies
โข Retail Pharmacies
By Region:
โข North America
โข Africa
โข Asia Pacific
โข Europe
โข Latin America
โข Middle East
๐๐จ ๐๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐ ๐๐๐ซ๐ @ https://www.coherentmarketinsights.com/insight/request-pdf/2019
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837